SANTA MONICA, Calif., April 28, 2020 -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and.
Opiant Pharmaceuticals (NASDAQ:OPNT) has had a rough three months with its share price down 7.9%. However, a closer...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 12) ACADIA Pharmaceuticals Inc (NASDAQ: ACAD ) Allergan ...
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
Opiant Pharmaceuticals, Inc. (“Opiant”) (OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, announced today that it is changing the format of its 2020 annual meeting of shareholders (the “2020 Annual Meeting”) from an in-person meeting to a virtual one due to public health concerns surrounding the outbreak of the novel coronavirus (COVID-19) and to prioritize the health and well-being of its employees, shareholders and other community members. Additionally, these shareholders can submit questions related to the matters to be voted on at the 2020 Annual Meeting during the live webcast of the meeting by using the instructions on the virtual meeting website.
By David Bautz, PhD NASDAQ:OPNT READ THE FULL OPNT RESEARCH REPORT Financial Update On March 4, 2020, Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) announced financial results for the fourth quarter and full year 2019. For the fourth quarter of 2019, Opiant reported total revenue of $7.7 million, including $7.2 million of revenue from the licensing agreement with Adapt Pharma Operations Limited, a
Roger Crystal has been the CEO of Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) since 2009. This analysis aims first to...
Q4 2019 Opiant Pharmaceuticals Inc Earnings Call
SANTA MONICA, Calif., May 26, 2020 -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug.
Opiant Pharmaceuticals, Inc. (“Opiant”) (OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced that it has signed a Letter of Intent with the National Center for Advancing Translational Sciences (NCATS) to collaborate on the development of OPNT004 (drinabant), a novel cannabinoid receptor antagonist, for the treatment of Acute Cannabinoid Overdose (ACO). NCATS is one of 27 divisions and centers of the National Institutes of Health (NIH). NCATS will provide development resources around certain pre-clinical activities and studies in order to support Opiant’s planned filing of an Investigational New Drug application for OPNT004.
Q3 2019 Opiant Pharmaceuticals Inc Earnings Call
SANTA MONICA, Calif., May 12, 2020 -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and.
Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) shareholders might understandably be very concerned that the share price...
By David Bautz, PhD NASDAQ:OPNT READ THE FULL OPNT RESEARCH REPORT Business Update NDA Filing for OPNT003 in Early 2021 Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) is developing OPNT003, an intranasal (IN) formulation of nalmefene (a naltrexone derivative), which the company is developing as a long-lasting opioid antagonist for the treatment of opioid overdose. In 2018, Opiant received a $7.4
Opiant Pharmaceuticals, Inc. (“Opiant”) (OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced that it has been awarded the second tranche of approximately $2.4 million from the total contract award of up to a maximum of approximately $4.6 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Health and Human Services Office of the Assistant Secretary for Preparedness and Response, to accelerate Opiant’s development of OPNT003, nasal nalmefene, a potent, long-acting opioid antagonist currently in development for the treatment of opioid overdose. Opiant intends to pursue a 505(b)(2) development path for OPNT003 and anticipates the potential to submit a New Drug Application for the drug and intranasal delivery device combination in the fourth quarter 2020.
The President has reconsidered his decision to ban the sale of flavored e-cigarettes in favor of conducting more research. Opiant Pharmaceuticals CEO Dr. Roger Crystal joins Yahoo Finance’s Brian Sozzi and Alexis Christoforous to discuss on The First Trade.
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]
By David Bautz, PhD NASDAQ:OPNT READ THE FULL OPNT RESEARCH REPORT Business Update R&D Meeting Highlights Pipeline of Addiction and Drug Overdose Treatments On October 17, 2019, Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) held a research and development meeting to highlight the companies most advanced programs for treating addiction and drug overdose. The slide presentation for the event can
SANTA MONICA, Calif., Feb. 24, 2020 -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and.
SANTA MONICA, Calif., March 04, 2020 -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and.